Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2024)

Barinthus Biotherapeutics has reported EBT Margin for 5 years, with the latest figure at 54.33% in Q3 2024.

• For the quarter ending Q3 2024, EBT Margin changed N/A year-over-year to 54.33%; the trailing twelve-month figure through Dec 2025 stood at 445.14% (down 3611.0% YoY), and the FY2024 full-year result was 409.03%, up 913237.0% from the prior year.
• EBT Margin for Q3 2024 stood at 54.33%, up from 7473.05% in the prior quarter.
• The five-year high for EBT Margin was 1668600.0% in Q4 2021, with the low at 48128.57% in Q2 2021.
• Historically, EBT Margin has averaged 104701.07% across 5 years, with a median of 659.43% in 2020.
• Annual changes were most pronounced in 2021 — EBT Margin soared 167206441 bps — and 2022, when it slumped 166895902 bps.
• Barinthus Biotherapeutics' EBT Margin stood at 3464.41% in 2020, then soared by 48264 bps to 1668600.0% in 2021, then tumbled by 100 bps to 359.02% in 2022, then tumbled by 1982 bps to 7473.05% in 2023, then soared by 99 bps to 54.33% in 2024.
• The last three EBT Margin figures came in at 54.33% (Q3 2024), 7473.05% (Q2 2023), and 4004.06% (Q1 2023), per Business Quant data.